Emtricitabine Didanosine

Zidovudine, lamivudine Didanosine, emtricitabine, stavudine, abacavir... [Pg.1079]

Nucleoside reverse transcriptase inhibitors (NRTIs) were the first class of medications approved for the management of HIV infection. They are structural analogues of nucleic acids. They undergo intracellular phosphorylation to a triphosphate metabolite and it is this metabolite that is pharmacologically active against reverse transcriptase. Drugs in this class include abacavir, adefovir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, and zidovudine. [Pg.387]

Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Zalcitabine, Zidovudine Tenofovir... [Pg.773]

Combination of 16 ARVs seven HIV protease inhibitors (amprenavir, atazanavir, indinavir, lopinavir, nelfmavir, ritonavir, and saquinavir), seven nucleoside reverse transcriptase inhibitors (abacavir, didanosine, emtricitabine, lamivudine, stavudine, zalcitabine, and zidovudine), and two nonnucleoside reverse transcriptase inhibitors (efavirenz and nevirapine)... [Pg.116]

At present there are seven NRTIs, which have been formally approved for the treatment of AIDS 3 -azido-2, 3 -dideoxythymidine (AZT, zidovudine), 2, 3 -dideoxyinosine (ddl, didanosine), 2, 3 -dideoxycytidine (ddC, zalcitabine), 2, 3 -didehydro-2, 3 -dideoxythymidine (d4T, stavudine), (—)-L-3 -thia-2, 3 -dideoxycytidine (3TC, lamivudine), cyclopentenyl V -cyclopropylaminopurine (abacavir, ABC), and (—)-L-5-fluoro-3 -thia-2, 3 -dideoxycytidine ((—)FTC, emtricitabine) (De Clercq 2004a) (Fig. 3). [Pg.73]

Zidovudine Didanosine Stavudine Lamivudine Abacavir Tenofovir Emtricitabine Nevirapine Efavirenz TMC125 Saquinavir Indinavir Lopinavir Fosamprenavir Atazanavir Tipranavir Darunavir Raltegravir Elvitegravir Enluvirtide Maraviroc Vicriviroc Bevirimat... [Pg.335]

Efavirenz and (didanosine or abacavir or stavudine) and (lamivudine or emtricitabine)... [Pg.1259]

Atazanavir or fosamprenavir or nelfinavir or saquinavir/ ritonavir, and zidovudine or stavudine or tenofovir or abacavir or didanosine, and lamivudine or emtricitabine... [Pg.1259]

Triple NRTI therapy is recommended only when a first-line or alternative first-line therapy with either an NNRTI-based or Pi-based regimen cannot be used. Abacavir plus zidovudine plus lamivudine is the only regimen approved by the DHHS. The following triple nucleoside therapy combinations have shown poor or limited efficacy, and should be avoided abacavir plus tenofovir plus lamivudine (or emtricitabine), and didanosine plus tenofovir plus lamivudine (or emtricitabine). [Pg.1259]

Drugs that should not be combined due to overlapping toxi-cities include amprenavir oral solution plus ritonavir oral solution, atazanavir plus indinavir (due to enhanced hyperbilirubinemia), and any combination of didanosine, stavudine, and zalcitabine. Emtricitabine and lamivudine should not be combined because of their similar chemical structures, and antagonism can result when lamivudine is combined with zalcitabine, or stavudine is combined with zidovudine. [Pg.1259]

Abacavir (Ziagen) Amprenavir (Agenerase) Delavirdine (Rescriptor) Didanosine [ddl] (Videx) Efavirenz (Sustiva) Efavirenz/Emtricitabine/ Tenofovir (Atripla) Fosamprenavir (Lexiva)... [Pg.37]

The present NRTIs available for the treatment of HIV are zidovudine (azidothymidine, AZT), stavu-dine (d4T), didanosine (ddl), lamivudine (3TC), dideoxycytidine (ddC, zalcitabine) and abacavir, emtricitabine and tenofovir disoproxil. Combination formulations are abcavir combined with zidovudine and lamivudine and the abacavir-lamivudine combination. [Pg.421]

TC Lamivudine ABC Abacavir d4T Stavudine ddC Zalcitabine ddl Didanosine TDF Tenofovir ZDV Zidovudine, also abbreviated as AZT FTC Emtricitabine NVP Nevirapine DLV Delavirdine EFV Efavirenz RTV, r Ritonavir Pl/r Ritonavir boosted protease inhibitor SQV Saquinavir IDV Indinavir LPV Lopinavir NEV Nelfinavir APV Amprenavir ATV Atazanavir DRV Darunavir... [Pg.550]

CMV Cytomegalovirus CYP Cytochrome P450 d4T Stavudine ddC Zalcitabine ddl Didanosine EBV Epstein-Barr virus FTC Emtricitabine... [Pg.1067]

Despite their widespread clinical use, direct nephrotoxicity has not been reported with zidovudine, emtricitabine or didanosine. Electrolyte disorders have been described but are uncommon. Hypokalemia was reported in didanosine treated patients, which may have been related to HIV infection or didanosine related diarrhea in somes though, hypokalemia occurred without diarrhea [77]. Symptomatic hypocalcemia, without changes in serum magnesium, phospho-... [Pg.387]

Efavirenz plus (lamivudine or emtricitabine) p/us didanosine except for pregnant women or women with pregnancy potential or... [Pg.2261]

Nevirapine plus (lamivudine or emtricitabine) plus zidovudine (or stavudine or didanosine)... [Pg.2261]

ABBREVIATIONS EFV, efavirenz 3TC, lamivudine AZT, zidovudine TDF, tenofovir disoproxil fumarate d4T, stavudine LPV/r, lopinavir/ritonavir coformulation FTC, emtricitabine NVP, nevirapine ddl, didanosine ATV, atazanavir fosAPV, fosamprenavir RTV, ritonavir IDV, indinavir NFV, nelfinavir SQV, saquinavir. [Pg.840]

Parameter Zidovudine Lamivudine Stavudine Didanosine Abacavir Zalcitabine Tenofovir Emtricitabine... [Pg.842]

FIGURE 50-3 Intracellular activation of nucleoside analog reverse transcriptase inhibitors. Drugs and phosphory-lated anabolites are abbreviated the enzymes responsible for each conversion are spelled out. The active antiretroviral anabolite for each drug is shown in the blue box. Key ZDV, zidovudine d4T, stavudine ddC, dideoxycytidine FTC, emtricitabine 3TC, lamivudine ABC, abacavir ddl, didanosine DF, disoproxil fumarate MP, monophosphate DP, diphosphate TP, triphosphate AMP, adenosine monophosphate CMP, cytosine monophosphate dCMP, deoxycytosine monophosphate IMP, inosine 5 -monophosphate PRPP, phosphoribosyl pyrophosphate NDR, nucleoside diphosphate. [Pg.843]

NRTIs are faulty version reverse transcriptase. Reproduction of HIV is stalled when HIV uses NRTI instead of the normal reverse transcriptase. Dmgs within this category include Abacavir (Ziagen, ABC), Abacavir, Lamivudine (Epzicom), Abacavir, Lamivudine, Zidovudine (Trizivir), Didanosine (Videx, ddl, Videx EC), Emtricitabine (Emtriva, FTC, Coviracil), Emtricitabine, Tenofovir DF (Truvada), Lamivudine (Epivir, 3TC), Lamivudine, Zidovudine (Combivir), Stavudine (Zerit, d4T), Tenofovir DF (Viread, TDF), Zalcitabine (Hivid, ddC), and Zidovudine (Retrovir, AZT, AZV). [Pg.343]

Nucleoside Analogue HIV Reverse Transcriptase Inhibitors as Drugs for the Treatment of HIV and Hepatitis B Zidovudine, Didanosine, Stavudine, Lamivudine, Abacavir, Emtricitabine and Entecavir... [Pg.123]

Food can reduce the extent of absorption of didanosine, possibly causing a loss in efficacy. The extent of absorption of zalcitabine and zidovudine is reduced slightly by food. Food does not affect the extent of absorption of abacavir, emtricitabine, lamivudine, and stavudine. [Pg.797]

Some combinations of NRTIs are potentially antagonistic (stavudine with zidovudine, lamivudine with zalcitabine) and some are expected to result in additive toxicity (didanosine with stavudine or zalcitabine, and possibly stavudine with zalcitabine). Some do not appear to result in additional benefits (emtricitabine with lamivudine), and some are considered inferior to other combinations (stavudine with lamivudine, zidovudine with zalcitabine or didanosine). None of these combinations are recommended. Combinations that are specifically recommended (with other antiretrovirals) include lamivudine with abacavir, didanosine or zidovudine, or didanosine with emtricitabine. Sole use of all triple NRTI regimens should generally be avoided, with the possible exception of abacavir or tenofovir , (p.806) with zidovudine and lamivudine. [Pg.800]

Tenofovir increases the levels of didanosine an increased risk of pancreatitis and peripheral neuropathy has been reported, and a high level of treatment failure. There is no pharmacokinetic interaction between tenofovir and abacavir, emtricitabine, lamivudine or stavudine. However, the combination of tenofovir, lamivudine and abacavir was unexpectedly associated with a high level of treatment failure. Triple-NRTI regimens invoiving tenofovir are not recommended, with the possibie exception of tenofovir, lamivudine and zidovudine. [Pg.806]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...